Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Stock Chart & Stats
$72.15
-$0.75(-2.14%)
At close: 4:00 PM EST
$72.15
-$0.75(-2.14%)
Day’s Range― - ―
52-Week Range$23.95 - $86.74
Previous CloseN/A
Volume126.35K
Average Volume (3M)2.41M
Market Cap
$11.92B
Enterprise Value$14.16B
Total Cash (Recent Filing)$2.68B
Total Debt (Recent Filing)$2.61B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding165,192,020
10 Day Avg. Volume2,538,477
30 Day Avg. Volume2,407,434
Financial Highlights & Ratios
PEG Ratio1.53
Price to Book (P/B)25.88
Price to Sales (P/S)13.41
P/FCF Ratio-39.55
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue15.01
Enterprise Value/Gross Profit15.27
Enterprise Value/Ebitda3.12
Forecast
1Y Price Target
$97.19Price Target Upside34.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$822.09M
Bulls Say, Bears Say
Bulls Say
Clinical ResultsLate-stage trial findings of a significant reduction in acute pancreatitis events together with open‑label evidence of declining liver fat strengthen the therapy's safety and efficacy story and could encourage broader adoption by clinicians and payers.
Commercial ExecutionDeployment of an expanded specialty field force and the shift from a development-stage to a commercial-stage company enhance launch capabilities and the ability to identify on‑label patients ahead of label expansion.
Regulatory ProgressFDA acceptance of a neurology filing under priority review and anticipated acceptance of the triglyceride filing can accelerate approval timelines and move expected sales nearer term compared with conservative forecasts.
Bears Say
Balance SheetElevated net debt relative to equity increases financial leverage and could pressure the company's valuation and limit flexibility for launches or further investment.
Guidance OutlookConservative annual revenue guidance combined with anticipated increases in gross‑to‑net discounts points to a potential for a larger non‑GAAP operating loss than investors expect, which may weigh on the stock.
Market SizeThe neurology indication targets a very small patient population, which constrains immediate commercial upside even if regulatory approval is achieved.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $11.92B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is May 06, 2026 which is in 38 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Feb 25, 2026. The company reported -$1.41 earnings per share for the quarter, missing the consensus estimate of -$1.319 by -$0.091.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -0.85.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 165,192,020 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$1.41 in its last earnings report, missing expectations of -$1.319. Following the earnings report the stock price went down -5.29%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.19 (34.71% Upside)
$97.19 (34.71% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 745.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.45%
12-Months-Change
Fundamentals
Return on Equity
-68.82%
Trailing 12-Months
Asset Growth
17.32%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Company Deck
IONS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive momentum: multiple successful launches (TRYNGOLZA, DAWNZERA), landmark Phase III data (olezarsen, zilganersen), 34% revenue growth in 2025, expanding commercial infrastructure and robust partner progress underpin confident guidance and multibillion-dollar peak potential for key programs. Notable near-term risks and conservatism tempering outlook include guidance assuming a standard sNDA review (delaying broader sHTG sales), expected TRYNGOLZA revenue decline during transition and pricing negotiations, projected non-GAAP operating losses as commercial investments continue, cash use for debt repayment, and binary clinical/regulatory readouts (e.g., HORIZON) that carry execution risk. Overall, positive operational and clinical achievements substantially outweigh these manageable near-term financial and timing risks.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$97.19
▲(34.71% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---